Therapixel

What is Therapixel?

Therapixel is a French software company specializing in artificial intelligence applied to medical imaging. Its flagship product, MammoScreen, supports breast cancer detection in mammography screening.

Key capabilities of Therapixel

• Lesion detection: finds suspicious soft tissue lesions and calcifications
• Malignancy assessment: characterizes and scores findings
• 2D and tomosynthesis: FDA clearance for 2D and digital breast tomosynthesis
• Priors and pre-reporting: case pre-check and pre-reporting features
• Clinical deployment: used across health networks
• Reader support: assists radiologists, not a replacement

How Therapixel works

MammoScreen analyzes mammogram images, detects suspicious soft tissue lesions and calcifications and assesses malignancy, presenting results to the radiologist. Updated versions add priors, case pre-check and pre-reporting.

Who uses Therapixel?

Therapixel reports a partnership with Mayo Clinic in June 2025 and with Onsite Women's Health in April 2025 for deployment across 150+ locations. Investors include Creazur, IT Translation, Omnes and M Capital.

Therapixel pricing

Therapixel does not publish prices. Licensing is quoted by the vendor.

Therapixel alternatives

Alternatives for imaging AI include Qynapse for neuroimaging and Optellum for lung cancer.